Use of tapinarof for the treatment of atopic dermatitis
US11497718B2 · kind B2 · utility
0Cited by
11References
21Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 13, 2019 |
| Grant date | Nov 15, 2022 |
| Priority date | — |
| Expiry date | Nov 13, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P17/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Topical compositions and methods for using topical compositions comprising tapinarof to treat mild to moderate atopic dermatitis are described herein. Also described are clinical endpoints for treatment of subjects diagnosed with mild to moderate atopic dermatitis, wherein about 5% to about 35% of body surface area was affected, and Investigator Global Assessment (IGA) score was greater than or equal to 3.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.